Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15958461 | 1.00 | GRM2 (0.52) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL15399382 | 0.76 | SMN1; SMN2 (0.57) | GRM2CMA1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15958463 | 0.76 | SMN1; SMN2 (0.57) | GRM2CMA1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL26116306 | 0.73 | GAA (0.51) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL28155226 | 0.71 | ALDH1A1 (0.53) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL17360667 | 0.71 | CMA1 (0.59) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL29136262 | 0.70 | GRM2 (0.50) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL1674206 | 0.70 | GRM2 (0.50) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL8348748 | 0.70 | GRM2 (0.56) | GRM2GAACMA1MMP1MMP13 | |
| SCHEMBL14686990 | 0.70 | MMP1 (0.62) | GRM2GAACMA1MMP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2874632-B1 | TRIAZINE COMPOUND HAVING PI3K-ALPHA AND MTOR INHIBITING ACTIVITY | SPHAERA PHARMA PTE LTD (SG) | 2020-06-17 | — | — | EP | disclosed |
| EP-2867238-B1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2017-08-09 | — | — | EP | disclosed |
| US-9630958-B2 | Triazine compounds | SPHAERA PHARMA PTE. LTD. (SG) | 2017-04-25 | — | — | US | disclosed |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2015-07-16 | — | — | US | disclosed |
| EP-2867238-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BioSciences Australia Pty Ltd (AU) | 2015-05-06 | — | — | EP | disclosed |
| US-8809359-B2 | Phenyl amino pyrimidine bicyclic compounds and uses thereof | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2014016849-A9 | NOVEL TRIAZINE COMPOUNDS | SPHAERA PHARMA PTE. LTD. (SG) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014000032-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005161-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY LTD (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005161-A1 | PHENYL AMINO PYRIMIDINE BICYCLIC COMPOUNDS AND USES THEREOF | JAK3, JAK1, JAK2 | GRM2 2539/4885GAA 4012/4885CMA1 2935/4885 |
| US-20150197515-A1 | NOVEL TRIAZINE COMPOUNDS | MTOR, PIK3R5, PIK3R2 | GRM2 2349/4885GAA 2217/4885CMA1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.